Novartis posts landmark CAR-T data as head-to-head rivalry with Kite Pharma looms
Vasant Narasimhan, chief medical officer of Novartis AG, looks on during a January 2017 news conference in Basel Michele Limina/Bloomberg
Novartis’ pioneering CAR-T drug CTL019 (tisagenlecleucel) scored high in treating diffuse large B-cell lymphoma (DLBCL), spotlighting numbers that will likely allow the pharma giant to plunge head-to-head in the market against its main initial rival, Kite Pharma. But Novartis also found itself defending its manufacturing operations Wednesday morning, as analysts zeroed in on a number of patients who couldn’t be treated in the study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.